SALT
LAKE CITY, Oct. 23, 2023 /PRNewswire/ --
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"),
a molecular diagnostics company with a unique, patented platform
for the development of molecular diagnostic tests, announced today
that the Company will be hosting a booth this week at the Caribbean
Association of Medical Technologies (CASMET) Scientific Symposium
and BGM, held in Barbados
October 22-26, 2023.
CASMET is an independent, non-governmental organization
representing more than 1500 medical laboratory professionals across
the Caribbean basin, a diverse
region with needs that the Company believes align with its mission
of increasing accessibility of affordable, high-quality diagnostics
to markets where they are in greatest demand.
In addition to a test for COVID-19 on its upcoming Co-Dx PCR
Home™ platform, which is currently undergoing clinical evaluations
on the platform in preparation for a submission to the FDA, Co-Dx
has several other infectious disease tests in varying stages of
development. Attendees interested in learning more about the
Company and this new platform are invited to visit Booth #14-15,
which will be open October 23-25.
More information about the conference can be found here.
The Co-Dx PCR Home platform is subject to FDA review and is
not available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets
state-of-the-art diagnostics technologies. The Company's
technologies are utilized for tests that are designed using the
detection and/or analysis of nucleic acid molecules (DNA or RNA).
The Company also uses its proprietary technology to design specific
tests for its Co-Dx PCR Home™ platform and to locate genetic
markers for use in applications other than infectious disease.
Forward-Looking Statements:
This press
release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
(PSLRA) that are subject to a number of risks and uncertainties.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking statements in
this release may include statements regarding our belief that our
new platform will help support the Company's worldwide efforts to
help prevent the spread of infectious diseases and our belief that
our new platform has the potential to dramatically improve access
to diagnostics and reduce healthcare costs. Actual results may
differ materially from those contemplated or anticipated by such
forward-looking statements. Readers of this press release are
cautioned not to place undue reliance on any forward-looking
statements. There can be no assurance that any of the anticipated
results will occur on a timely basis or at all due to certain risks
and uncertainties, a discussion of which can be found in our Risk
Factors disclosure in our Annual Report on Form 10-K, filed with
the Securities and Exchange Commission (SEC) on March 16, 2023, and in our other filings with the
SEC. The Company does not undertake any obligation to update any
forward-looking statement relating to matters discussed in this
press release, except as may be required by applicable securities
laws.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-host-booth-at-casmet-symposium-october-23-25-301964215.html
SOURCE Co-Diagnostics